drug-discovery

Proteolysis Targeting Chimera (PROTAC) is an innovative drug discovery strategy that utilizes bifunctional small molecules to bring a target protein (POI) into proximity with an E3 ubiquitin ligase, thereby inducing ubiquitination of the pathogenic protein and its subsequent degradation by the proteasome. PROTACs exhibit a novel mechanism of action, catalytic efficiency, high selectivity, and bro…

Nature Reviews Drug Discovery, Published online: 12 June 2026; doi:10.1038/d41573-026-00099-1 David Reese, Amgen’s inaugural Chief Technology Officer, discusses how inconspicuous AI achievements stand to transform drug discovery.

The Acceleration Consortium (AC) at the University of Toronto and the Structural Genomics Consortium (SGC) announced today a formalized partnership to help tackle a persistent challenge in biomedicine and early drug discovery: the development of bioactive molecules with drug-like properties, advancing our understanding of human health and disease and jump-starting new drug discovery programs.

At Microsoft Build 2026, the software giant’s annual developer conference, held June 2 and 3 in San Francisco, the life sciences AI company Causaly announced a collaboration with Microsoft aimed at one of drug discovery’s earliest and most consequential decisions: which biological targets are worth pursuing. Causaly runs an agentic AI platform that reads across… The post Causaly and Microsoft tar…

Using AI to speed up the interpretation of missense variants and support drug discovery

Nature Communications, Published online: 05 June 2026; doi:10.1038/s41467-026-73863-x In this work, the authors develop a machine learning–based enhanced sampling workflow to target the intrinsically disordered AR-NTD, identifying druggable conformations and enabling transferable modeling of ligand binding for rational drug discovery.

High-throughput screening (HTS) is widely used in modern drug discovery. It enables batch activity testing of compounds and provides important support for the identification of active compounds. However, its screening efficiency and accuracy need to be improved. To address this issue, artificial intelligence (AI) has been gradually integrated into the HTS workflow. Leveraging the advantages of ma…

Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs. The finding also reveals important limitations in today's artificial intelligence tools for drug discovery. The study, published in the June 2 online issue of the …

Find out about how biotech companies are trying to address the limits the first generation of WEE1 inhibitors faced. The post Can WEE1 inhibitors finally make replication stress druggable? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly pro…

Recent advances in artificial intelligence have enabled Southwest Research Institute (SwRI) to identify nearly two dozen antiviral compounds that could potentially treat a rare species of Ebola virus (Bundibugyo virus) currently affecting the Democratic Republic of Congo.

Our two guests this week: Quin Wills, CEO of Ochre Bio, and Stéphane Barges, CEO of Lexogen. The post The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is st…

As the pace of modern drug discovery accelerates, the industry is increasingly recognizing that a breakthrough molecule is only as effective as its ability to reach the target site.

Targeted protein degradation has become one of the most promising strategies in modern drug discovery, enabling scientists to eliminate disease-causing proteins instead of merely blocking them.

Isomorphic Labs, the Alphabet-backed AI drug design company led by Sir Demis Hassabis, who shared the 2024 Nobel Prize in Chemistry with John Jumper for their work on the protein structure prediction platform AlphaFold, announced a $2.1 billion Series B on May 12. The total outside capital raised to date is about $2.6 billion. Thrive… The post Alphabet-spinoff Isomorphic Labs raises $2.1 billion …

New projects in AI-enabled drug discovery, Parkinson’s disease therapeutics, and colorectal cancer immunotherapy advance the School’s strategic research mission. The post School awards inaugural FOCUS seed funding to three research teams appeared first on Eshelman School of Pharmacy .

An experimental drug developed using artificial intelligence shows promise in treating opioid use disorder. The medication significantly lowered fentanyl intake in rodents by targeting serotonin receptors, promoting healthy brain adaptation without relying on traditional opioid-based treatments.

Methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of morbidity and mortality worldwide, largely due to penicillin-binding protein 2a (PBP2A), a low-affinity transpeptidase encoded by mecA. To address the challenge of this highly flexible target, we developed an integrated discovery framework combining conformational ensemble analysis with deep generative modeling. Extensive…

Nature Reviews Drug Discovery, Published online: 08 May 2026; doi:10.1038/d41573-026-00078-6 First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions

Headquartered in Tokyo – with a European Research facility in Munich – the company focuses on developing and delivering innovative new medicines, alongside advanced drug discovery and delivery methodologies, which serve patients globally. CPP members benefit from direct connection with EMBL’s world-leading molecular biology research, services, and technology development, and their support enables…

Nature Biomedical Engineering, Published online: 24 April 2026; doi:10.1038/s41551-026-01667-x DeepDrugDiscovery is an AI-powered screening platform incorporating ADMET and blood–brain barrier penetrability predictions to successfully identify mTOR-independent autophagy enhancers that can cross the blood–brain barrier for Alzheimer’s disease therapy.